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A B S T R A C T
The aim of the study was to determine the place and role of serologic methods in detecting Helicobacter pylori (H.
pylori) infection, on the basis of estimated enzyme-linked immunosorbent assay (ELISA) and complement fixation test
(CFT) sensitivity and specificity. A total of 549 patients were included in the study. ELISA and CFT as serologic methods
were compared with invasive methods (rapid urease test – CLO test, culture, histology). The sensitivity of serologic meth-
ods was above 90%, and their specificity was around 80%. Study results confirmed the value, reliability and usefulness
of serologic methods in the detection of H. pylori infection.
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Introduction
Helicobacter pylori (H. pylori), a bacterium that mark-
ed the 20th century, is the most common etiologic factor
of peptic ulcer, especially in duodenum1–6. It is associated
with non-cardiac carcinoma of the stomach (diffuse and
intestinal type)7, and its association with some extra-
intestinal diseases has also been postulated8–10. Diagnos-
tic methods for the detection of H. pylori infection are di-
vided into two groups: invasive and noninvasive11. All
invasive methods are based on endoscopy with biopsy
samples of gastric mucosa obtained for direct (histology
and culture) or indirect (rapid urease test) diagnosis.
Rapid urease test or CLO test has a sensitivity of
90–95% and specificity of 98%. In 90% of patients with
negative CLO test gastric mucosa is usually unchanged.
However, 5–10% of tested samples can be CLO negative
because of inadequate number of the bacteria present in
the sample12–14.
Histology is a rapid, reliable and reproducible me-
thod. This method can also be used to determine the
morphological characteristics of gastritis. The sensitivity
and specificity of the method are around 95%13,15,16. Cul-
ture requires a gastric mucosa biopsy sample; however,
at least two samples (antrum/corpus) are needed due to
uneven colonization of gastric mucosa. This is particu-
larly important on taking samples for the control of H.
pylori eradication. The sensitivity of culture is 90–95%
and specificity around 100%13,17. In addition to identify-
ing the strain of H. pylori, molecular methods are used to
determine the genes responsible for different factors of
virulence6,13.
Noninvasive methods are based on the detection of
urease activity (urea breath test), presence of specific an-
tibodies in serum and/or saliva of infected person (serol-
ogy), and in recent time on antigen detection in stool.
Urea breath test detects the presence of H. pylori in
stomach by detecting the H. pylori urease. This test has a
high sensitivity and specificity (95–98% both)13,18,19. Urea
breath test is usually used to prove H. pylori eradication
at 4 weeks of antimicrobial therapy completion.
H. pylori induces inflammatory reactions in gastric
mucosa, thus activating specific humoral immunity re-
sponse, which in turn results in the production of specific
IgM, IgA and IgG antibodies. Specific IgM antibodies are
produced in a minority of infected persons. They are spe-
cific but difficult to detect. The sensitivity of tests for the
detection of specific IgA antibodies, which are bound to
the surface of the bacteria and prevent their adhesion to
the cells, is 60–80%. Specific IgG antibodies, subclasses
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IgG1, IgG2 and IgG4, are most commonly present in the
serum of infected individuals. The tests used for their de-
tection have a high sensitivity (94%) and specificity
(98%), and are most commonly used in the diagnosis of
H. pylori infection. During the course of infection, the
levels of antibodies are insignificantly changed20,21. Diffe-
rent serologic tests are used to detect H. pylori infection:
agglutination, latex agglutination, passive hemaggluti-
nation, complement fixation test (CFT), enzyme-linked
immunosorbent assay (ELISA) and immunoblot test22.
Serologic diagnosis has a special place in epidemiological
studies23.
Since recently, immunoenzyme procedures have been
used for direct detection of H. pylori antigen in stool
sample. These procedures are used to detect active infec-
tion as well as its eradication. The procedure sensitivity
is 80–90% and specificity around 100%17–23.
The aim of this study was to determine the place and
role of serologic methods in the diagnosis of H. pylori in-
fection, on the basis of estimated ELISA and CFT sensi-
tivity and specificity.
Materials and Methods
The study was performed during the 1994–2002 pe-
riod at Merkur University Hospital and Prison Infirmary
in Zagreb, and included 549 patients (Table 1): 436 pa-
tients (M/F 250/186, mean age 53.4 years) regularly at-
tending Endoscopy Laboratory, Merkur University Hos-
pital, and 113 patients (M/F 102/11, mean age 41.9 years)
from Prison Infirmary. All patients suffered pain in the
upper abdomen with dyspeptic symptoms. Prior to enter-
ing the study, the patients signed the informed consent
form for gastroscopy. The study design was approved by
the Hospital Ethics Committee.
Study patients underwent clinical examination and
gastroscopy. During gastroscopy 7 histological samples of
gastric mucosa were obtained (3 from the corpus and 4
from the antrum). One sample was taken for rapid ure-
ase test (CLO test, Delta West, Bentley, Western Austra-
lia), two samples were obtained for culture (Skirrow
agar, Mueller-Hinton agar, E-test), and four samples for
histology (Giemsa modified technique and Warthin-Star-
ry stains; Sydney classification system of gastritis).
Patients were included into H. pylori positive group if
the result of histology and urease test and in some cases
of culture were positive for H. pylori. The H. pylori nega-
tive group included patients in whom histology, urease
test and culture were negative. Histology16, urease test14
and culture for H. pylori17 were done according to the
previously described methodology. The patients who had
been taking any kind of antibiotic therapy or a combina-
tion of antisecretory and antibiotic therapy for one month
before endoscopy were excluded from the study.
Serum samples were tested with commercial ELISA
(Eurospital, Trieste, Italy) and CFT (Institute Virion,
Zurich, Switzerland). The tests were performed accord-
ing to the manufacturer’s instructions. Borderline test
values were established in line with the manufacturer’s
instructions, to interpret the results obtained.
ELISA: each serum sample diluted 1:200 was applied
onto a microtiter plate with previously bound H. pylori
antigen. The antigen-antibody complex was proven by
sheep antihuman IgG antibodies labeled with alkaline
phosphatase and incubated with chromogen substrate.
The substrate absorption was determined by ELISA rea-
der (Multiscan, Titertek, MCC/340, Finland). An index of
IgG antibodies equal or higher than 40% was considered
as a positive result.
CFT: complement fixation antibodies (IgM, IgG) were
proven by H. pylori strain Lior type 1. Each serum sam-
ple was diluted with a 1:10 Veronal buffer and incubated
for 30 minutes at 56 °C to inactivate the complement
present in the serum. Then serum sample as well as posi-
tive and negative serum controls were diluted from 1:10
to 1:160, edging certain dilution of antigen and comple-
ment. The test included controls to detect anticomple-
mentary activity in each sample tested as well as control
for the complement used (0.5, 1.0, 1.5 and 2.0 units of
complement). The result of CFT was assessed on the ba-
sis of hemolysis inhibition. The inhibition of 50% or more
was considered positive, indicating the presence of anti-
bodies in the respective dilution. Antibody titer of less
than 1:30 was considered negative.
To determine the specificity of the serologic methods
used we tested sera of 227 patients with pain in the up-
per abdomen, free from dyspeptic symptoms and without
H. pylori in the gastric mucosa biopsy samples (histology,
rapid urease test, cultures were negative) (Table 2).
Statistics
The 2 test for dependent and independent samples,
and the test of proportions were used. Statistical analysis
was done by use of the Microstat software. Statistical sig-
nificance was set at p<0.05.
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TABLE 1
PATIENTS GENERAL CHARACTERISTICS
N
Mean age ()
(yrs)
Merkur University Hospital patients 436 53.4
Men 250 53.2
Women 186 54.1
Prison Infirmary patients 113 41.9
Men 102 42.2
Women 11 40.0
Total 549 51.8
Results
Sensitivity and specificity of ELISA and CFT
The sensitivity of ELISA and CFT was evaluated by
testing serum samples of 276 patients with dyspeptic
symptoms. Patients underwent gastroscopy, and H. pylori
was detected in biopsy samples by culture, CLO test and
histology. The sensitivity of serologic methods was above
90%, i.e. 94.9% for ELISA and 93.1% for CFT (Table 2).
The specificity of ELISA and CFT was assessed by
testing serum samples of 227 patients free from dyspep-
tic symptoms and without H. pylori detected in biopsy
samples of gastric mucosa (histology, rapid urease test,
cultures were negative). The specificity of serologic me-
thods was around 80%, i.e. 80.1% for ELISA and 78.4%
for CFT (Table 2).
Evaluation of invasive and noninvasive serologic
methods in patients with dyspeptic symptoms
On the basis of gastroscopy findings, 549 patients
were divided into two groups: group 1 including patients
without endoscopically verified ulcer and/or ulcer scar (168
patients with nonulcer dyspepsia), and group 2 including
patients with ulcer and/or ulcer scar (381 patients).
In all patients, biopsy samples of gastric mucosa were
tested for the presence of H. pylori (culture, CLO test,
histology). Serum samples were tested by ELISA and
CFT to detect specific antibodies against H. pylori. Re-
sults obtained in patient sera by use of invasive and
noninvasive methods and their evaluation are shown in
Table 3.
A statistically significant difference between ELISA
and invasive methods was only recorded in the group of
patients with ulcer (scar) (2=6.45, p=0.09), however,
only at a 90% level. Comparison of CFT and invasive
methods showed no statistically significant difference in
either group of patients (2=6.02, ns). Comparison of
ELISA and CFT results with the results of each individ-
ual invasive method produced a statistically significant
difference in both groups of patients only between posi-
tive ELISA results and positive culture results (2=4.57,
p<0.05). Proportion testing showed a statistically higher
number of H. pylori infection detected in the group with
ulcer (scar) by both serologic and invasive methods:
ELISA (Z=4.59, p<0.001), CFT (Z=5.70, p<0.001), his-
tology (Z=3.09, p<0.001), rapid urease test (Z=2.7, p<
0.005) and culture (Z=5.23, p<0.001).
On analysis of overall results obtained by serologic
and invasive methods (Table 3) using the test of propor-
tions, there was no statistically significant difference be-
tween ELISA and CFT (Z=0.82, ns), or between ELISA
and histology (Z=1.02, ns). However, ELISA showed a
statistically significantly higher sensitivity than either
urease test (Z=1.9, p<0.05) or culture (Z=7.27, p<0.001).
CFT was statistically significantly more sensitive only
compared with culture (Z=6.36, p<0.001), whereas the
sensitivity of histology (Z=0.19, ns) and urease (Z=1.06,
ns) yielded no statistically significant difference.
Discussion
A variety of methods have been used in the diagnosis
of H. pylori infection. Most of the methods are invasive
because they require gastroscopy to obtain biopsy sam-
ples of gastric mucosa for further analysis and detection
of H. pylori infection. Culture is necessary to test for
antimicrobial susceptibilities. The other group of meth-
ods are noninvasive because they do not require gas-
troscopy and H. pylori infection can be detected by the
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TABLE 2
EVALUATION OF SENSITIVITY AND SPECIFICITY OF ELISA AND CFT
N
ELISA CFT Sensitivity Specificity
n + n – n + n – ELISA (%) CFT (%) ELISA (%) CFT (%)
H. pylori (+) 276 262 14 257 19 94.9 93.1 – –
H. pylori (–) 227 45 182 49 178 – – 80.1 78.4
N – total number of tested patients, (+) – H. pylori positive patients, (–) – H. pylori negative patients, ELISA – enzyme-linked im-
munosorbent assay, CFT – complement fixation test
TABLE 3
COMPARISON OF ENDOSCOPY FINDINGS WITH RESULTS OF SEROLOGIC AND INVASIVE METHODS IN STUDY PATIENTS
Endoscopy finding N
ELISA
n (%)
CFT
n (%)
Histology
n (%)
CLO
n (%)
Culture
n (%)
Non-ulcer dyspepsia 168 142 (84.5) 127 (75.5) 134 (79.7) 126 (75.0) 65 (38.6)
Ulcer (scar) 381 365 (95.8) 354 (92.9) 341 (89.5) 323 (84.7) 244 (64.0)
Total 549 507 (92.3)*/** 481 (87.6)*** 475 (86.5) 449 (81.7)* 309 (56.2)**/***
N – total number of patients, ELISA – enzyme-linked immunosorbent assay, CFT – complement fixation test, CLO – rapid urease test,
*p<0.05, **p<0.001, ***p<0.001
presence of antibodies in serum samples (serology), by
the presence of labeled CO2 in exhaled breath upon in-
gestion of labeled urea, and by the bacterial urease activ-
ity (urea breath test).
ELISA is most widely used in the detection (qualita-
tive) and measurement (quantitative) of the level of spe-
cific antibodies in serum samples. The previously used
non-purified antigens have been replaced by purified
products of urease and/or proteins of great molecular
mass extracted from glycine. Immunoblot (Western blot)
has recently been used as the method of choice for evalu-
ation of immunity response against different H. pylori
antigens (VacA, CagA). Antibodies against these antigens
indicate an increased risk of ulcer and gastric adenocarci-
noma, and are used as a confirmation test for the results
obtained by other serologic methods24–26. ELISA detects
the presence of individual classes of specific antibodies
and can also determine the level of these antibodies in se-
rum samples. ELISA tests for the detection of IgG anti-
bodies have a more than 90% sensitivity and specificity27.
The sensitivity of serologic methods used in the present
study was more than 90%. The sensitivity of ELISA was
94.9%, exceeding the sensitivity of CFT of 93.1%. The
specificity was slightly lower: 80.1% for ELISA and 78.4%
for CFT, which is consistent with the results reported
elsewhere for commercial serologic procedures28,29.
The sensitivity and specificity are important parame-
ters which show the purpose of using serologic methods
in the diagnosis of H. pylori and evaluation of the meth-
ods employed. Different values of the sensitivity and
specificity reported from various studies could be ex-
plained by the use of different normal values and »stan-
dard« methods. Some studies employed only one invasive
method (culture, histology or rapid urease test) as a stan-
dard method, whereas others employed a combination of
two or more methods. In our study, we chose histology,
culture and rapid urease test as standard methods.
The sensitivity and specificity of the superior sero-
logic tests are the same as the sensitivity and specificity
of urea breath test30. The sensitivity of serologic tests is
slightly higher than the sensitivity of invasive me-
thods31,32, as confirmed by our results. In the group of pa-
tients with ulcer and/or ulcer scar, a statistically signifi-
cant difference was recorded in the detection of infection
between ELISA (at 90% level) and invasive methods. The
difference in sensitivity between serologic and invasive
methods may be caused by difficulty in obtaining biopsy
material due to the poorly visible site of H. pylori coloni-
zation on the gastric mucosa32–36 and the effect of anti-
bacterial therapy. Some authors37,38 emphasize a dispro-
portion between the grade of infection and the degree of
immune response, pointing to inter-individual differ-
ences in the immune response to infection. There are lit-
erature reports on cases of H. pylori infection detected by
invasive methods yet not accompanied by corresponding
antibody levels, which results from a weak or absent re-
sponse of the immune system39,40. In atrophic gastritis,
serology may be the only tool to detect H. pylori infec-
tion41–43. In addition, invasive tests do not perform well
in patients with bleeding ulcers44–46. It should be noted
that the sensitivity and specificity of serologic methods
are reduced in persons above 60 years of age as the result
of weak immune response47.
The incidence of H. pylori negative »nonspecific gas-
tritis« is higher in the elderly, which may be due to the
small number of bacteria present in gastric mucosa, pre-
vious infection treated with antibiotics, gastric mucosa
atrophy, and gastritis of other etiology (autoimmune gas-
tritis, prolonged therapy with nonsteroidal anti-inflam-
matory drugs). Like serologic methods, histologic meth-
ods also are less reliable in detecting H. pylori infection
in the elderly. Tests for antibody detection in saliva sam-
ples have a lower sensitivity and specificity than tests for
the detection of serum antibodies48,49.
In spite of these shortcomings associated with sero-
logic methods, simultaneous usage of a serologic method
with one or more invasive methods will significantly in-
crease the overall sensitivity of the diagnostic work-up.
This is important in patients with clinical signs of severe
infection and in those aged >45, who are at a higher risk
of developing serious complications. Some authors sug-
gest that patients younger than 45 without alarming
symptoms can be screened for the presence of infection
using only serologic methods50. Today, the recommenda-
tion is to use more methods for detecting H. pylori infec-
tion because all known methods yield some 5–10% of
false positive or false negative results51.
Our results showed the use of serologic methods in
the detection of H. pylori infection (primary infection)
with commercial CFT and ELISA tests to be helpful, reli-
able and fully justified. Commercial products were evalu-
ated by testing the sera from a selected patient popula-
tion. The sensitivity, specificity and reference values
were determined, as they differ from population to popu-
lation. Three standard methods, i.e. histology, culture
and urease test, were used on evaluation of the serologic
method sensitivity and specificity. The sensitivity of sero-
logic methods exceeded 90%; however, ELISA showed
higher sensitivity and specificity than CFT (94.9% vs
93.1% and 80.1% vs 78.4%, respectively).
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MJESTO I ULOGA SEROLO[KIH METODA U UTVR\IVANJU INFEKCIJE HELICOBACTER PYLORI
S A @ E T A K
Cilj nam je bio na temelju utvr|enih vrijednosti osjetljivosti i specifi~nosti metoda ELISA (imunoenzimski test) i
reakcije vezanja komplementa odrediti mjesto i zna~enje serolo{kih metoda u otkrivanju infekcije Helicobacter pylori
(H. pylori). U ispitivanje je bilo uklju~eno 549 bolesnika, a navedene serolo{ke metode su uspore|ene s invazivnim
metodama (CLO test, izolacija, histolo{ki pregled). Osjetljivost serolo{kih metoda prema{ila je 90%, dok je specifi~nost
bila pribli`no 80%. Ovim radom je dokazana vrijednost, pouzdanost i opravdanost uporabe serolo{kih postupaka u
otkrivanju infekcije H. pylori.
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